132 related articles for article (PubMed ID: 38598369)
1. Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells.
Wang X; Zhao Y; Li X; Zhang Q; He J; Liu Y; Li M; Luo Z
Nano Lett; 2024 Apr; ():. PubMed ID: 38598369
[TBL] [Abstract][Full Text] [Related]
2. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
3. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
4. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J; Zhang Z; Wang D; Bhattacharya S; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
bioRxiv; 2023 Aug; ():. PubMed ID: 37577590
[TBL] [Abstract][Full Text] [Related]
5. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J; Zhang Z; Bhattacharya S; Wang D; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102137. PubMed ID: 38384444
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in drug delivery systems for targeting cancer stem cells.
Duan H; Liu Y; Gao Z; Huang W
Acta Pharm Sin B; 2021 Jan; 11(1):55-70. PubMed ID: 33532180
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
[TBL] [Abstract][Full Text] [Related]
8. Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.
Chang M; Gao F; Pontigon D; Gnawali G; Xu H; Wang W
J Am Chem Soc; 2023 Jun; 145(25):14155-14163. PubMed ID: 37327395
[TBL] [Abstract][Full Text] [Related]
9. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
[TBL] [Abstract][Full Text] [Related]
10. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy.
Huang J; Yao Z; Li B; Ping Y
J Control Release; 2023 Sep; 361():270-279. PubMed ID: 37541594
[TBL] [Abstract][Full Text] [Related]
12. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
Liu Y; Xu Q; Deng F; Zheng Z; Luo J; Wang P; Zhou J; Lu X; Zhang L; Chen Z; Zhang Q; Chen Q; Zuo D
J Exp Clin Cancer Res; 2023 Feb; 42(1):38. PubMed ID: 36721234
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts promote the stemness of CD24
Li Y; Wang R; Xiong S; Wang X; Zhao Z; Bai S; Wang Y; Zhao Y; Cheng B
J Mol Med (Berl); 2019 Feb; 97(2):243-255. PubMed ID: 30564864
[TBL] [Abstract][Full Text] [Related]
14. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
15. Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF-κB and JAK/STAT3 signaling in human hepatocellular carcinoma.
Luo Y; Yang Z; Su L; Shan J; Xu H; Xu Y; Liu L; Zhu W; Chen X; Liu C; Chen J; Yao C; Cheng F; Zhang C; Ma Q; Shen J; Qian C
Cancer Lett; 2016 Jun; 375(2):390-399. PubMed ID: 27000993
[TBL] [Abstract][Full Text] [Related]
16. Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression.
Chen YJ; You ML; Chong QY; Pandey V; Zhuang QS; Liu DX; Ma L; Zhu T; Lobie PE
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617312
[TBL] [Abstract][Full Text] [Related]
17. Suppression of ovarian cancer by low-intensity ultrasound through depletion of IL-6/STAT3 inflammatory pathway-maintained cancer stemness.
Gong T; Zhang P; Jia L; Pan Y
Biochem Biophys Res Commun; 2020 Jun; 526(3):820-826. PubMed ID: 32273089
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
19. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
20. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer.
Jin J; Wu Y; Zhao Z; Wu Y; Zhou YD; Liu S; Sun Q; Yang G; Lin J; Nagle DG; Qin J; Zhang Z; Chen HZ; Zhang W; Sun S; Luan X
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]